Liver tumor promoting effects of fenbendazole in rats. (1999)

Peer-Reviewed Study · Shoda T, Onodera H, Takeda M, Uneyama C, Imazawa T, Takegawa K, Yasuhara K, Watanabe T, Hirose M, Mitsumori K · 1999

Shoda T et al., 1999: Rat two-stage hepatocarcinogenesis study showing that fenbendazole at 600-3600 ppm in the diet causes periportal hepatocellular hypertrophy and induces CYP1A2, 2B1 and 4A1. The paper is a tumour-promotion study, not a cancer-risk study in humans.

Periportal hepatocellular hypertrophy, characterized by a marked increase in smooth endoplasmic reticulum, was observed in the groups given > or =600 ppm with or without DEN initiation.

Shoda T et al., 1999: Rat two-stage hepatocarcinogenesis study showing that fenbendazole at 600-3600 ppm in the diet causes periportal hepatocellular hypertrophy and induces CYP1A2, 2B1 and 4A1. The paper is a tumour-promotion study, not a cancer-risk study in humans. Animal study (rat, two-stage liver carcinogenesis model); 70 male Fischer 344 rats; Japan (National Institute of Health Sciences, Tokyo); fenbendazole in diet at 0, 70, 200, 600, 1800 or 3600 ppm for 8 weeks after diethylnitrosamine initiation. Funder: not stated; no grant list. Declared conflicts: none recorded. Product: fenbendazole, manufacturer not stated. Comparator: DEN-initiated versus saline controls, and untreated diet controls. The liver enzyme induction reported here is the same CYP1A effect measured in pigs under C5. Study type: animal.